A plain-English look at Danaher's revenue, profit margins, and market value as it focuses on scientific instruments and diagnostics.
From Real Estate to Lab Benches
Most companies don't start out selling real estate and end up making diagnostic equipment, but that's exactly the arc Danaher Corp has traveled. In 1984, its founders converted a real estate organization into an industrial manufacturer, then reshaped it repeatedly through mergers, acquisitions, and divestitures.
A Focused Life Sciences Business
Today Danaher is a different company than the industrial conglomerate it once was. Since the late 2023 divestiture of its environmental and applied solutions group, Veralto, Danaher has concentrated on manufacturing scientific instruments and consumables for the life sciences and diagnostics industries. It's classified in the Medical Devices industry and is headquartered in Washington, District of Columbia.
A Long Public History
Danaher has been publicly traded since its IPO in December 1978, giving it decades of history on the market under the ticker NYSE: DHR. The company now employs approximately 60,000 people worldwide.
Revenue at Scale
In fiscal year 2025, Danaher generated $24.6 billion in revenue. That's a substantial base of business for a company now centered on scientific instruments and diagnostics rather than sprawling industrial operations.
Profit Margins Tell a Story
Danaher turned that revenue into $3.6 billion in net income for the year, meaning the company was solidly profitable. Its gross margin stood at 59.1%, and its net margin was 14.7%. Those figures suggest a business that keeps a meaningful share of what it earns after covering the cost of goods and other expenses.
Assets on the Balance Sheet
Beyond the income statement, Danaher's balance sheet shows total assets of $83.5 billion, reflecting the scale of its manufacturing and instrument-related operations built up over decades of acquisitions and restructuring.
Growth in Reverse
Not every metric points upward. Revenue declined 17% from FY2021 to FY2025, a period that includes the Veralto divestiture and a narrower focus on life sciences and diagnostics. A shrinking top line after shedding a major business segment is a different story than a company losing ground in its core markets, and readers should weigh that context when looking at the decline.
Market Value and Share Price
Danaher's market capitalization currently sits at $130.4 billion, with shares recently trading at $199.05 on a 15-minute delayed basis. That share price is 18% below the stock's 52-week high, indicating some pullback from its recent peak trading levels.
What the Valuation Reflects
The company is valued at a price-to-earnings ratio of 39.4, a figure that reflects how the market is pricing Danaher's earnings relative to its current profitability. Danaher also pays a dividend yielding about 0.8% annually, a modest but steady return to shareholders alongside any change in share price.
What the Numbers Add Up To
Taken together, the figures describe a profitable, multibillion-dollar company that has narrowed its focus to life sciences and diagnostics after years of portfolio changes, even as its overall revenue has contracted from 2021 levels. This is factual reporting based on public filings and market data, not investment advice.
